AI assistant
VALIRX PLC — AGM Information 2016
Oct 12, 2016
7998_dva_2016-10-12_d60432f7-7e1a-46da-a61b-076cc46ce243.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 3595M
ValiRx PLC
12 October 2016
VALIRX PLC
("ValiRx", "the Company" or "the Group")
RESULT OF GENERAL MEETING
London, UK., 12 October 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces that at a General Meeting of the Company held earlier today, all resolutions were passed providing the Company with the necessary headroom to issue the warrants pursuant to the last placing as announced on 2 September 2016.
This announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
*** ENDS ***
For more information, please contact:
| ValiRx Plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
| Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
| Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 [email protected] |
| Mark Treharne, Corporate Development Manager | Tel: +44 (0) 7736 564 686 [email protected] |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0) 20 7148 7900 |
| Liam Murray / Jo Turner | |
| Northland Capital Partners Limited (Joint Broker) | Tel: +44 (0) 203 861 6625 |
| Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking) |
|
| Beaufort Securities Limited (Joint Broker) | Tel: +44 (0) 207 382 8300 |
| Jon Belliss |
Notes for Editors
ValiRx Plc
ValiRx is a biotechnology oncology focussed company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's three classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMBLLFFQBFBFBV